Kirsten Raun
Vice President - Scientific Novo Nordisk
Seminars
Wednesday 2nd December 2026
Translating Dual GLP-1/Amylin Agonism into Meaningful Glycaemic Control & Weight Loss: Lessons from Zenagamtide
11:30 am
- Examine the Phase II dose-response findings for once-weekly zenagamtide, including HbA1c reductions of up to 1.71 percentage points and body-weight loss of up to 14.6% at 36 weeks, to assess the clinical potential of combining GLP-1 and amylin receptor agonism within a single molecule
- Explore how dose escalation, receptor balance and exposure influenced efficacy and gastrointestinal tolerability, enabling developers to refine therapeutic windows and make more informed dose-selection decisions for next-generation co-agonists
- Translate the findings into future development strategy, from identifying the patient populations most likely to benefit to determining how dual GLP-1/amylin assets can differentiate from established incretins as zenagamtide advances toward Phase III development
